



NEWS RELEASE  
FOR IMMEDIATE RELEASE

TSX: AMF

## **UK GOVERNMENT CLARIFIES PROCESS TO VERIFY A BLOOD TEST FOR vCJD AND RELEASES AMORFIX BLINDED PANEL RESULTS**

**TORONTO, ON, February 1, 2008** – Amorfix Life Sciences announced today that the Expert Advisory Group of the British National Institute for Biological Standards and Controls (NIBSC) has now established the process to verify the performance of an acceptable blood test for vCJD. Based on the performance of its EP-vCJD™ assay, Amorfix received and accepted an invitation from the British government to further qualify the assay using British blood samples. The NIBSC will provide blood samples from scrapie-infected sheep, normal human controls and patients with vCJD.

“It is an honour to be selected to access these precious vCJD patient samples and move closer to securing the blood supply,” said Dr. Neil Cashman, Chief Scientific Officer for Amorfix. “Amorfix is ready to test these samples.”

In addition, Amorfix received its EP-vCJD™ assay results from testing a blinded panel of spiked human blood samples. These samples had been provided by NIBSC as part of an ongoing tender process to supply testing kits for a study of the prevalence of markers of vCJD in UK blood donors. Dr. Cashman, will present these results at the 12<sup>th</sup> Annual Transmissible Spongiform Encephalopathies conference in Baltimore, Maryland on February 11<sup>th</sup>.

“With the positive results from the spiked human blood panel, Amorfix has successfully completed the second step in the ongoing tender process to test for the prevalence of vCJD in UK blood donors,” said Dr. George Adams, Chief Executive Officer of Amorfix. “We have manufactured the necessary kits to test 60,000 blood samples for prevalence testing.”

Recent evidence has suggested that people may be infected for decades before showing signs of vCJD. The number of people who contracted the disease by consuming BSE-positive products is unknown. To date, four people have been officially reported to have been infected through blood transfusion from donors who years later developed symptoms and died from vCJD. Thousands of people who received vCJD-positive plasma fractions are currently being monitored to determine how many have been infected. Blood transfusion services in low-risk countries refuse to take blood from people who have lived in high-risk countries, where BSE-positive cattle were prevalent, to prevent the spread of the disease. A screening test for vCJD is needed urgently to prevent the spread of vCJD through the blood transfusion services worldwide.

## **About Amorfix**

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

*This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

- 30 -

### **For more information, please contact:**

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6959 Fax: (416) 847-6899 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6929 Fax: (416) 847-6899 james.parsons@amorfix.com
---	---